TDMS Study 05058-02 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
ROXARSONE
NTP Experiment-Test: 05058-02 Report: PEIRPT05
Study Type: CHRONIC Date: 09/12/94
Route: DOSED FEED Time: 08:59:01
Facility: Southern Research Institute
Chemical CAS #: 121-19-7
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05058-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ROXARSONE Date: 09/12/94
Route: DOSED FEED Time: 08:59:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATD 0.01% 0.02%
CONTROL
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50
Early Deaths
Natural Death 14 15 12
Moribund Sacrifice 21 17 21
Accidently Killed 1
Survivors
Terminal Sacrifice 14 18 17
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (45) (45) (47)
Intestine Small, Duodenum (47) (50) (46)
Adenoma 1 (2%)
Intestine Small, Ileum (46) (49) (47)
Intestine Small, Jejunum (49) (50) (46)
Liver (50) (50) (50)
Hemangiosarcoma 1 (2%)
Hepatocellular Carcinoma 1 (2%)
Hepatocellular Carcinoma, Multiple 1 (2%)
Hepatocellular Adenoma 1 (2%)
Sarcoma 1 (2%)
Mesentery (27) (27) (30)
Sarcoma 1 (3%)
Pancreas (50) (50) (49)
Salivary Glands (48) (49) (47)
Stomach, Glandular (50) (50) (49)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (50) (49) (50)
Adrenal Gland, Medulla (50) (49) (50)
Islets, Pancreatic (50) (50) (49)
Adenoma 1 (2%)
Parathyroid Gland (46) (44) (47)
Pituitary Gland (49) (46) (49)
Pars Distalis, Adenoma 6 (12%) 3 (7%) 4 (8%)
Page 2
NTP Experiment-Test: 05058-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ROXARSONE Date: 09/12/94
Route: DOSED FEED Time: 08:59:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATD 0.01% 0.02%
CONTROL
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
Pars Intermedia, Adenoma 2 (4%)
Thyroid Gland (49) (49) (49)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (49) (49) (50)
Luteoma 1 (2%)
Sarcoma 1 (2%)
Uterus (50) (50) (50)
Adenocarcinoma 1 (2%)
Hemangioma, Multiple 1 (2%)
Leiomyoma 1 (2%)
Sarcoma 1 (2%)
Cervix, Polyp Stromal 1 (2%)
Endometrium, Polyp Stromal 1 (2%) 1 (2%)
Vagina (1)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50)
Lymph Node (50) (50) (50)
Renal, Sarcoma 1 (2%)
Lymph Node, Mandibular (40) (48) (42)
Lymph Node, Mesenteric (48) (48) (46)
Spleen (50) (50) (49)
Thymus (39) (42) (44)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (50) (50)
Adenocarcinoma 1 (2%)
Adenocarcinoma, Multiple 1 (2%)
Skin (50) (50) (50)
Squamous Cell Papilloma 1 (2%)
Trichoepithelioma 1 (2%)
Subcutaneous Tissue, Hemangioma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 05058-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ROXARSONE Date: 09/12/94
Route: DOSED FEED Time: 08:59:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATD 0.01% 0.02%
CONTROL
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (6) (2) (2)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (49) (50)
Spinal Cord (50) (50) (50)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50)
Alveolar/Bronchiolar Adenoma 1 (2%) 3 (6%) 3 (6%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 1 (2%) 2 (4%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (2) (3) (3)
Adenoma 1 (50%) 2 (67%) 1 (33%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (49)
Sarcoma 1 (2%)
Urinary Bladder (49) (50) (50)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Lymphoma Malignant Histiocytic 1 (2%)
Lymphoma Malignant Lymphocytic 1 (2%) 1 (2%) 1 (2%)
Lymphoma Malignant Mixed 12 (24%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 4
NTP Experiment-Test: 05058-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ROXARSONE Date: 09/12/94
Route: DOSED FEED Time: 08:59:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE UNTREATD 0.01% 0.02%
CONTROL
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 24 11 18
Total Primary Neoplasms 32 16 25
Total Animals with Benign Neoplasms 11 9 13
Total Benign Neoplasms 13 12 13
Total Animals with Malignant Neoplasms 18 3 5
Total Malignant Neoplasms 19 4 12
Total Animals with Metastatic Neoplasms 1
Total Metastatic Neoplasm 1
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 5
NTP Experiment-Test: 05058-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ROXARSONE Date: 09/12/94
Route: DOSED FEED Time: 08:59:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATD 0.01% 0.02%
CONTROL
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50
Early Deaths
Moribund Sacrifice 17 9 11
Natural Death 6 1 6
Survivors
Terminal Sacrifice 27 40 33
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (42) (42) (48)
Adenocarcinoma, Metastatic 1 (2%)
Intestine Large, Cecum (50) (49) (49)
Intestine Small, Duodenum (49) (45) (47)
Intestine Small, Jejunum (49) (49) (48)
Liver (50) (50) (50)
Adenocarcinoma, Metastatic 1 (2%)
Adenoma, Multiple 1 (2%)
Hemangiosarcoma, Multiple 1 (2%)
Hepatocellular Carcinoma 3 (6%) 8 (16%) 5 (10%)
Hepatocellular Carcinoma, Multiple 1 (2%)
Hepatocellular Adenoma 9 (18%) 8 (16%) 2 (4%)
Mesentery (4) (4) (6)
Adenocarcinoma, Metastatic 1 (17%)
Pancreas (49) (50) (50)
Stomach, Forestomach (50) (50) (50)
Squamous Cell Papilloma 1 (2%)
Stomach, Glandular (50) (50) (50)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
None
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (50) (50) (49)
Adenoma 1 (2%) 1 (2%)
Subcapsular, Adenoma 1 (2%) 3 (6%)
Adrenal Gland, Medulla (50) (50) (49)
Pheochromocytoma NOS 1 (2%)
Pheochromocytoma Benign 3 (6%)
Page 6
NTP Experiment-Test: 05058-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ROXARSONE Date: 09/12/94
Route: DOSED FEED Time: 08:59:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATD 0.01% 0.02%
CONTROL
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
Thyroid Gland (50) (48) (50)
Follicular Cell, Adenoma 2 (4%) 2 (4%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ductus Deferens (2)
Preputial Gland (11) (13) (7)
Carcinoma 1 (9%)
Prostate (50) (50) (49)
Seminal Vesicle (2) (3) (2)
Testes (50) (50) (50)
Hemangiosarcoma 1 (2%)
Interstitial Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (49) (50)
Lymph Node (50) (49) (50)
Axillary, Sarcoma, Metastatic, Skin 1 (2%)
Inguinal, Sarcoma, Metastatic, Skin 1 (2%)
Inguinal, Lumbar, Sarcoma, Metastatic, Skin 1 (2%)
Mediastinal, Adenocarcinoma, Metastatic 1 (2%)
Lymph Node, Mandibular (48) (42) (43)
Lymph Node, Mesenteric (43) (48) (47)
Spleen (50) (50) (50)
Hemangiosarcoma 2 (4%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50)
Squamous Cell Carcinoma 1 (2%)
Abdominal, Axillary, Subcutaneous Tissue,
Sarcoma, Multiple, Metastatic, Skin 1 (2%)
Hindlimb, Subcutaneous Tissue, Sarcoma 1 (2%)
Subcutaneous Tissue, Fibroma 4 (8%) 4 (8%) 4 (8%)
Subcutaneous Tissue, Fibrosarcoma 6 (12%) 3 (6%) 7 (14%)
Subcutaneous Tissue, Hemangioma 1 (2%)
Subcutaneous Tissue, Lipoma 1 (2%)
Page 7
NTP Experiment-Test: 05058-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ROXARSONE Date: 09/12/94
Route: DOSED FEED Time: 08:59:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATD 0.01% 0.02%
CONTROL
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - cont
Subcutaneous Tissue, Sarcoma 4 (8%) 4 (8%) 5 (10%)
Subcutaneous Tissue, Sarcoma, Multiple 1 (2%) 1 (2%) 1 (2%)
Subcutaneous Tissue, Schwannoma NOS 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50)
Pelvis, Osteoma 1 (2%)
Skeletal Muscle (1) (2) (2)
Abdominal, Thoracic, Adenocarcinoma,
Multiple, Metastatic 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Peripheral Nerve (50) (50) (50)
Sciatic, Sarcoma, Metastatic, Skin 1 (2%)
Spinal Cord (50) (50) (50)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50)
Adenocarcinoma, Metastatic 1 (2%)
Alveolar/Bronchiolar Adenoma 4 (8%) 2 (4%) 9 (18%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (2%)
Alveolar/Bronchiolar Carcinoma 6 (12%) 2 (4%) 1 (2%)
Hepatocellular Carcinoma, Multiple,
Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 2 (4%) 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%) 1 (2%)
Sarcoma, Metastatic, Skeletal Muscle 1 (2%)
Squamous Cell Carcinoma, Multiple,
Metastatic, Skin 1 (2%)
Nose (48) (49) (48)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (5) (6) (4)
Adenoma 1 (20%) 2 (33%) 3 (75%)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05058-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ROXARSONE Date: 09/12/94
Route: DOSED FEED Time: 08:59:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATD 0.01% 0.02%
CONTROL
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50)
Adenocarcinoma, Metastatic 1 (2%)
Ureter (1)
Transitional Epithelium, Carcinoma 1 (100%)
Urinary Bladder (50) (50) (50)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50)
Lymphoma Malignant Histiocytic 2 (4%)
Lymphoma Malignant Mixed 3 (6%) 1 (2%) 3 (6%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 9
NTP Experiment-Test: 05058-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ROXARSONE Date: 09/12/94
Route: DOSED FEED Time: 08:59:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE UNTREATD 0.01% 0.02%
CONTROL
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 35 30 34
Total Primary Neoplasms 57 45 51
Total Animals with Benign Neoplasms 18 20 20
Total Benign Neoplasms 23 24 26
Total Animals with Malignant Neoplasms 26 18 21
Total Malignant Neoplasms 32 21 23
Total Animals with Metastatic Neoplasms 6 2 2
Total Metastatic Neoplasm 6 5 9
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 2 2
Total Uncertain Neoplasms 2 2
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 10
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------
--multipart-boundary
Content-type: text/plain
Range: bytes 58074-58074/58074
--multipart-boundary--